Brief: Bright Minds Biosciences Announces Receipt Of Nasdaq Deficiency Letter Regarding Independent Director And Audit Committee Requirements
08/02/2023 23:29
Feb 8 (Reuters) - Bright Minds Biosciences Inc
DRUG.CD :
* BRIGHT MINDS BIOSCIENCES ANNOUNCES RECEIPT OF NASDAQ
DEFICIENCY
LETTER REGARDING INDEPENDENT DIRECTOR AND AUDIT COMMITTEE
REQUIREMENTS
Source text for Eikon: ID:nGNXl6vrv
Further company coverage: DRUG.CD
Recent news on Bright Minds Biosciences
See all newsBright Minds Biosciences slips after increased $175 mln stock sale
Brief: Bright Minds Biosciences Announces Pricing Of Upsized US$175 Million Public Offering Of Common Stock At $90.00 Per Share
Bright Minds Biosciences falls after $100 mln equity offering launched
Brief: Bright Minds To Announce Topline Results For BMB-101 Phase 2 Trial In On Jan 6
Brief: Bright Minds Biosciences Files For Offering Of Up To 1.6 Million Common Shares By The Selling Securityholders